• Cloud DX (CDX) announces a brokered private placement of convertible debenture units for gross proceeds of up to $3,000,000
  • The agents have an option to sell up to 450 additional convertible debenture units for maximum aggregate gross proceeds of $3,450,000
  • The company intends to use the net proceeds of the offering for sales, marketing, research and development
  • The offering is expected to close on or about September 23, 2021
  • Cloud DX Inc. (CDX) opened trading at C$0.23 per share

Cloud DX (CDX) has announced a brokered private placement of up to 3,000 convertible debenture units for gross proceeds of up to $3,000,000.

Echelon Wealth Partners Inc. has agreed to act as lead agent and sole book runner on behalf of a syndicate of investment dealers. The agents have an option to sell up to 450 additional convertible debenture units for maximum aggregate gross proceeds of $3,450,000.

Each debenture unit will consist of $1,000 principal amount unsecured convertible debenture and 1,430 common share purchase warrants. The debentures will mature 36 months from the date of issuance and shall bear interest at a rate of 10% per annum. Interest will be payable quarterly on the last business day of each quarter, commencing on December 31, 2021.

The company intends to use the net proceeds of the offering for sales, marketing, research and development, and for general working capital purposes.

The offering is expected to close on or about September 23, 2021.

Accelerating virtual healthcare’s future, Cloud DX is making healthcare better for everyone. The company’s Connected Health remote patient monitoring platform is used by healthcare enterprises and care teams across North America to virtually manage chronic disease, enable ageing in place and deliver hospital-quality post-surgical care.

Cloud DX Inc. (CDX) opened trading at C$0.23 per share.

More From The Market Online

PharmAla Biotech launches educational portal for MDMA

PharmAla Biotech (CSE:MDMA) launches its Prescribers Portal for medical practitioners to learn more about MDMA.

Cancer-fighting pharma stock eyes 2027 regulatory approval

Theralase Technologies (TSXV:TLT), a cancer-fighting pharma stock, expands its team with two clinical research associates.

PharmaDrug-PharmaTher Holdings JV submits clinical, regulatory package

Sairiyo Therapeutics, a PharmaDrug (CSE:PHRX) and PharmaTher Holdings (CSE:PHRM) joint venture, pursues a human clinical study in Australia.